Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
The remarkable speed of the company’s cystic fibrosis triplet approval will not distract attention from its price.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
More data with voxelotor shouldn’t hurt the project’s bid for accelerated approval, but there are still doubts about its effect on a harder patient outcome.
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.